MedTrace Logo

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients

NCT04888312 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2025-10-08

No results posted yet for this study

Summary

Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.

Conditions

Interventions

BIOLOGICAL

CD40 agonist mitazalimab in combination with chemotherapy

Mitazalimab administered intravenously every 14 days in combination with standard of care chemotherapy modified FOLFIRINOX.

Sponsors & Collaborators

  • Alligator Bioscience AB

    lead INDUSTRY

Principal Investigators

  • Yago Pico de Coaña, PhD · Alligator Bioscience AB

  • Jean-Luc van Laethem, Prof. MD · Hospital Erasme

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-17
Primary Completion
2026-06-01
Completion
2026-06-30
FDA Drug
Yes

Countries

  • Belgium
  • France
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04888312 on ClinicalTrials.gov